Andrej Sali

Andrej Sali is a professor of computational biology at the University of California at San Francisco in the department of bioengineering and therapeutic sciences, department of pharmaceutical chemistry and the California Institute for Quantitative Biosciences (QB3). Dr. Sali's research interests focus on developing and applying computational methods for determining structures and functions of proteins and their assemblies.

Previously, he was as associate professor and assistant professor at The Rockefeller University. He has been professionally recognized as a Sinsheimer Scholar, an Alfred P. Sloan Research Fellow, an Irma T. Hirschl Trust Career Scientist and the recipient of the Zois Award of Science Ambassador of Republic of Slovenia. He is an editor of the journal Structure and a founder of Prospect Genomix, which merged with Structural Genomix and was then acquired by E. Lilly & Co.

Dr. Sali received his B.S. in chemistry from the University of Ljubljana, Slovenia, and his Ph.D. from Birkbeck College, University of London. He completed his postdoctoral training at Harvard University.

Andrej Sali is the Founder at Global Blood Therapeutics, based in United States, North America. With a background in Biotechnology, Andrej Sali has a rich history of leadership and innovation.Andrej Sali studied BS Chemistry at University of Ljubljana. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.